# Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

> **NCT02279615** · PHASE4 · UNKNOWN · sponsor: **St. Joseph's Healthcare Hamilton** · enrollment: 200 (estimated)

## Conditions studied

- Overactive Bladder
- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Tamsulosin

## Key facts

- **NCT ID:** NCT02279615
- **Lead sponsor:** St. Joseph's Healthcare Hamilton
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279615, "Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02279615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*